Biogen
NEWS
Bayer isn’t the only company to announce changes to its leadership team this morning. Editas, Biogen, Takeda, Merck and Vedere Bio also announced leadership changes.
This particular renewal panel discussion took an unexpected turn, focusing on Biogen’s controversial drug.
The company indicated that its timeline for an accelerated approval request for its own Alzheimer’s drug, donanemab, was no longer on schedule for the first quarter after the CMS draft guidance.
Alfred Sandrock Jr., the former head of research and development at Biogen, has taken a position on the board of directors of Cambridge, Mass.-based Voyager Therapeutics.
Biogen announced it was exercising its option to participate in Genentech’s development of mosunetuzumab under a long-standing collaboration for antibodies targeting CD20.
One week after Johnna Rossell departed Biogen for Enzyvant, Biogen announced two more members of its board are leaving.
Clinical trial news definitely picked up this final week of January. Here’s a look.
Biogen is selling its nearly 50% stake in Samsung Bioepis for $2.3 billion. The move will provide Biogen with additional capital while preparing to cut additional costs through a rumored employee layoff.
Biogen and its partner Eisai Company released additional details about the Phase IV post-marketing study of the drug.
JOBS
IN THE PRESS